Selectis Health Narrows Annual Loss to $(0.34) EPS on $41.4M Revenue, Operating Cash Flow Turns Positive
GBCS has more than doubled off its 52-week low of $0.405 on light trading volume (0.3× avg).
Summary
Selectis Health reported its 2025 annual financial results from its 10-K filing, detailing $41.44 million in total revenue and a net loss of $(0.34) per share. The company demonstrated significant operational improvements year-over-year, narrowing its net loss from $(0.80) per share in 2024 and improving operating income. Revenue increased by 6% year-over-year, primarily driven by higher Medicaid reimbursement rates. Notably, operating cash flow turned positive at $1.88 million, supporting working capital and property improvements. This indicates a positive trajectory for the micro-cap company, with management citing portfolio reshaping and cost management as key drivers. Investors will be watching for continued progress in profitability and sustained positive cash flow.
At the time of this announcement, GBCS was trading at $4.35 on OTC in the Life Sciences sector, with a market capitalization of approximately $13.3M. The 52-week trading range was $0.41 to $6.25. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.